// App-Quantinova.ai

2198 : Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Researchers

Presenter

  • Gregory Cheng

Principal Investigators

  • James B Bussel

  • Paul Burgess

  • Kalpana Bakshi

  • Andres Brainsky

  • Christine K Bailey

Medical Centers

  • Department of Pediatrics, Division of Hematology, Weill Medical College of Cornell University, New York, NY

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

Locations

  • United States

  • Hong Kong

Companies

  • GlaxoSmithKline plc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Drug-induced liver injury

  • Immune thrombocytopenia

  • Myocardial infarction

  • Deep vein thrombosis

  • Pulmonary embolism

  • Thrombocytopenia

  • Venous thrombosis

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Eltrombopag

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved